Posted on 13/05/2009 in Pharmaceutical Company Restructures Novartis has stated Jonathan Symonds is well suited to take on the role of chief financial officer (CFO) at the company.
He currently works at Goldman Sachs as the managing director of investment banking. Previous roles include KPMG partner, Zeneca's finance director and chief financial officer at AstraZeneca.
Mr Symonds will join Novartis on September 1st and will report to Raymund Breu, who is due to retire on March 31st 2010 after 35 years with the firm.
"Jonathan Symonds' financial expertise, broad industry experience and deep knowledge of the healthcare industry make him especially suited to take on the responsibilities of CFO of Novartis from Raymund Breu," remarked chairman and chief executive officer of the company Dr Daniel Vasella.
Earlier this month, the European Commission approved Novartis' Glivec to become the first treatment across the continent to reduce the risk of relapse in adults who have undergone surgery to remove gastrointestinal stromal tumours.
As well as applying to all 27 EU member states, the decision is also valid in Iceland and Norway. There have been furhter authorisations of the treatment in Switzerland, the US and other countries.Other news stories from 13/05/2009
Read more in the Zenopa News Archive
How this news is generated
|
